Which has higher earnings & valuation, CHE or MEDP?

Medpace has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.70 $265.24M $19.91 26.30 Medpace $2.78B 6.03 $451.12M $17.06 35.21

Is CHE or MEDP more profitable?

Medpace has a net margin of 17.67% compared to Chemed's net margin of 10.60%. Medpace's return on equity of 110.15% beat Chemed's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% Medpace 17.67% 110.15% 24.84%

Does the media favor CHE or MEDP?

In the previous week, Medpace had 28 more articles in the media than Chemed. MarketBeat recorded 47 mentions for Medpace and 19 mentions for Chemed. Chemed's average media sentiment score of 1.17 beat Medpace's score of 1.07 indicating that Chemed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 16 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 34 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, CHE or LH?

Labcorp has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.70 $265.24M $19.91 26.30 Labcorp $13.95B 1.95 $876.50M $12.09 27.78

Is CHE or LH more profitable?

Chemed has a net margin of 10.60% compared to Labcorp's net margin of 6.99%. Chemed's return on equity of 31.77% beat Labcorp's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% Labcorp 6.99% 16.74% 7.81%

Does the media favor CHE or LH?

In the previous week, Chemed had 10 more articles in the media than Labcorp. MarketBeat recorded 19 mentions for Chemed and 9 mentions for Labcorp. Chemed's average media sentiment score of 1.17 beat Labcorp's score of 0.42 indicating that Chemed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 16 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Labcorp 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, DGX or CHE?

Quest Diagnostics has higher revenue and earnings than Chemed. Quest Diagnostics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quest Diagnostics $11.56B 2.32 $992M $9.42 25.81 Chemed $2.53B 2.70 $265.24M $19.91 26.30

Is DGX or CHE more profitable?

Chemed has a net margin of 10.60% compared to Quest Diagnostics' net margin of 9.18%. Chemed's return on equity of 31.77% beat Quest Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Quest Diagnostics 9.18% 16.01% 7.27% Chemed 10.60% 31.77% 18.90%

Does the media favor DGX or CHE?

In the previous week, Quest Diagnostics had 8 more articles in the media than Chemed. MarketBeat recorded 27 mentions for Quest Diagnostics and 19 mentions for Chemed. Quest Diagnostics' average media sentiment score of 1.35 beat Chemed's score of 1.17 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 21 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 16 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, CHE or GH?

Chemed has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.70 $265.24M $19.91 26.30 Guardant Health $1.18B 18.32 -$416.28M -$3.49 N/A

Is CHE or GH more profitable?

Chemed has a net margin of 10.60% compared to Guardant Health's net margin of -38.33%. Chemed's return on equity of 31.77% beat Guardant Health's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% Guardant Health -38.33% N/A -25.40%

Does the media prefer CHE or GH?

In the previous week, Guardant Health had 13 more articles in the media than Chemed. MarketBeat recorded 32 mentions for Guardant Health and 19 mentions for Chemed. Guardant Health's average media sentiment score of 1.21 beat Chemed's score of 1.17 indicating that Guardant Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 16 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Guardant Health 24 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Which has higher earnings and valuation, CHE or TEM?

Chemed has higher revenue and earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.70 $265.24M $19.91 26.30 Tempus AI $1.27B 9.09 -$245.03M -$1.44 N/A

Is CHE or TEM more profitable?

Chemed has a net margin of 10.60% compared to Tempus AI's net margin of -17.77%. Chemed's return on equity of 31.77% beat Tempus AI's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% Tempus AI -17.77% -50.28% -10.33%

Does the media prefer CHE or TEM?

In the previous week, Chemed and Chemed both had 19 articles in the media. Chemed's average media sentiment score of 1.17 beat Tempus AI's score of 0.66 indicating that Chemed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 16 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tempus AI 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Chemed (CHE) Competitors

$523.57 +3.30 (+0.63%)

As of 08/28/2026 03:58 PM Eastern

Compare

CHE vs. MEDP, LH, DGX, GH, and TEM

Should you buy Chemed stock or one of its competitors? Chemed's main competitors and comparable companies include Medpace (MEDP), Labcorp (LH), Quest Diagnostics (DGX), Guardant Health (GH), and Tempus AI (TEM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Chemed compare to Medpace?

Chemed (NYSE:CHE) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Medpace has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.70	$265.24M	$19.91	26.30
Medpace	$2.78B	6.03	$451.12M	$17.06	35.21

95.9% of Chemed shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 3.3% of Chemed shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Chemed currently has a consensus target price of $530.75, indicating a potential upside of 1.37%. Medpace has a consensus target price of $584.18, indicating a potential downside of 2.74%. Given Chemed's higher possible upside, research analysts plainly believe Chemed is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

In the previous week, Medpace had 28 more articles in the media than Chemed. MarketBeat recorded 47 mentions for Medpace and 19 mentions for Chemed. Chemed's average media sentiment score of 1.17 beat Medpace's score of 1.07 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	16 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	34 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Chemed has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Medpace has a net margin of 17.67% compared to Chemed's net margin of 10.60%. Medpace's return on equity of 110.15% beat Chemed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
Medpace	17.67%	110.15%	24.84%

Summary

Medpace beats Chemed on 12 of the 16 factors compared between the two stocks.

How does Chemed compare to Labcorp?

Chemed (NYSE:CHE) and Labcorp (NYSE:LH) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

In the previous week, Chemed had 10 more articles in the media than Labcorp. MarketBeat recorded 19 mentions for Chemed and 9 mentions for Labcorp. Chemed's average media sentiment score of 1.17 beat Labcorp's score of 0.42 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	16 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Labcorp	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.9% of Chemed shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 3.3% of Chemed shares are held by company insiders. Comparatively, 0.8% of Labcorp shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Chemed has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Chemed pays an annual dividend of $2.80 per share and has a dividend yield of 0.5%. Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 0.9%. Chemed pays out 14.1% of its earnings in the form of a dividend. Labcorp pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Chemed has raised its dividend for 16 consecutive years.

Chemed presently has a consensus price target of $530.75, indicating a potential upside of 1.37%. Labcorp has a consensus price target of $330.00, indicating a potential downside of 1.76%. Given Chemed's higher possible upside, equities research analysts clearly believe Chemed is more favorable than Labcorp.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Labcorp	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

Chemed has a net margin of 10.60% compared to Labcorp's net margin of 6.99%. Chemed's return on equity of 31.77% beat Labcorp's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
Labcorp	6.99%	16.74%	7.81%

Labcorp has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.70	$265.24M	$19.91	26.30
Labcorp	$13.95B	1.95	$876.50M	$12.09	27.78

Summary

Chemed beats Labcorp on 11 of the 19 factors compared between the two stocks.

How does Chemed compare to Quest Diagnostics?

Quest Diagnostics (NYSE:DGX) and Chemed (NYSE:CHE) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

88.1% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 0.9% of Quest Diagnostics shares are owned by insiders. Comparatively, 3.3% of Chemed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.4%. Chemed pays an annual dividend of $2.80 per share and has a dividend yield of 0.5%. Quest Diagnostics pays out 36.5% of its earnings in the form of a dividend. Chemed pays out 14.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has increased its dividend for 14 consecutive years and Chemed has increased its dividend for 16 consecutive years.

In the previous week, Quest Diagnostics had 8 more articles in the media than Chemed. MarketBeat recorded 27 mentions for Quest Diagnostics and 19 mentions for Chemed. Quest Diagnostics' average media sentiment score of 1.35 beat Chemed's score of 1.17 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	21 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	16 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics presently has a consensus price target of $235.31, indicating a potential downside of 3.21%. Chemed has a consensus price target of $530.75, indicating a potential upside of 1.37%. Given Chemed's higher possible upside, analysts clearly believe Chemed is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Quest Diagnostics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Chemed has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Quest Diagnostics has higher revenue and earnings than Chemed. Quest Diagnostics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.56B	2.32	$992M	$9.42	25.81
Chemed	$2.53B	2.70	$265.24M	$19.91	26.30

Chemed has a net margin of 10.60% compared to Quest Diagnostics' net margin of 9.18%. Chemed's return on equity of 31.77% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
Chemed	10.60%	31.77%	18.90%

Summary

Chemed beats Quest Diagnostics on 11 of the 20 factors compared between the two stocks.

How does Chemed compare to Guardant Health?

Chemed (NYSE:CHE) and Guardant Health (NASDAQ:GH) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Chemed has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.70	$265.24M	$19.91	26.30
Guardant Health	$1.18B	18.32	-$416.28M	-$3.49	N/A

Chemed has a net margin of 10.60% compared to Guardant Health's net margin of -38.33%. Chemed's return on equity of 31.77% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
Guardant Health	-38.33%	N/A	-25.40%

95.9% of Chemed shares are owned by institutional investors. Comparatively, 92.6% of Guardant Health shares are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 5.6% of Guardant Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Chemed presently has a consensus target price of $530.75, indicating a potential upside of 1.37%. Guardant Health has a consensus target price of $183.78, indicating a potential upside of 13.80%. Given Guardant Health's stronger consensus rating and higher possible upside, analysts plainly believe Guardant Health is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Guardant Health	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

In the previous week, Guardant Health had 13 more articles in the media than Chemed. MarketBeat recorded 32 mentions for Guardant Health and 19 mentions for Chemed. Guardant Health's average media sentiment score of 1.21 beat Chemed's score of 1.17 indicating that Guardant Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	16 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Guardant Health	24 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Chemed has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Guardant Health has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

Summary

Guardant Health beats Chemed on 9 of the 17 factors compared between the two stocks.

How does Chemed compare to Tempus AI?

Chemed (NYSE:CHE) and Tempus AI (NASDAQ:TEM) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Chemed has higher revenue and earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.70	$265.24M	$19.91	26.30
Tempus AI	$1.27B	9.09	-$245.03M	-$1.44	N/A

Chemed has a net margin of 10.60% compared to Tempus AI's net margin of -17.77%. Chemed's return on equity of 31.77% beat Tempus AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
Tempus AI	-17.77%	-50.28%	-10.33%

Chemed currently has a consensus price target of $530.75, indicating a potential upside of 1.37%. Tempus AI has a consensus price target of $65.69, indicating a potential upside of 2.58%. Given Tempus AI's stronger consensus rating and higher possible upside, analysts clearly believe Tempus AI is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Tempus AI	2 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.41

95.9% of Chemed shares are owned by institutional investors. Comparatively, 24.2% of Tempus AI shares are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 24.3% of Tempus AI shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Chemed and Chemed both had 19 articles in the media. Chemed's average media sentiment score of 1.17 beat Tempus AI's score of 0.66 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	16 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tempus AI	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Chemed has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Tempus AI has a beta of 3.58, indicating that its share price is 258% more volatile than the broader market.

Summary

Chemed beats Tempus AI on 9 of the 15 factors compared between the two stocks.

Get Chemed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHE vs. The Competition

Export

Metric	Chemed	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$6.84B	$9.87B	$7.20B	$24.17B
Dividend Yield	0.53%	2.56%	2.54%	3.71%
P/E Ratio	26.30	34.69	273.16	29.99
Price / Sales	2.70	4.87	640.19	96.22
Price / Cash	21.22	120.59	76.74	32.24
Price / Book	8.24	4.00	12.98	7.67
Net Income	$265.24M	$312.92M	$3.48B	$1.07B
7 Day Performance	-3.28%	-1.34%	0.13%	-0.32%
1 Month Performance	-2.10%	0.93%	7.08%	1.84%
1 Year Performance	14.16%	15.34%	24.67%	13.37%

Chemed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHE Chemed	3.5854 of 5 stars	$523.57 +0.6%	$530.75 +1.4%	+14.2%	$6.84B	$2.53B	26.30	15,811	News Coverage Positive News
MEDP Medpace	2.9775 of 5 stars	$620.03 -0.1%	$584.18 -5.8%	+26.3%	$17.33B	$2.53B	36.34	6,200	News Coverage Insider Trade
LH Labcorp	4.056 of 5 stars	$339.38 +0.9%	$330.00 -2.8%	+20.8%	$27.28B	$13.95B	28.07	71,000
DGX Quest Diagnostics	4.4855 of 5 stars	$243.96 -0.2%	$235.31 -3.5%	+33.7%	$26.97B	$11.04B	25.90	57,000	Positive News
GH Guardant Health	3.1202 of 5 stars	$163.18 -4.4%	$183.78 +12.6%	+139.5%	$22.91B	$982.02M	N/A	2,506	Positive News Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CHE) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemed (CHE) Competitors